Skip to Content

Olumiant Dosage

Generic name: baricitinib 2mg
Dosage form: tablet, film coated

Medically reviewed by Drugs.com. Last updated on Nov 13, 2019.

Dosage in Rheumatoid Arthritis

The recommended dose of OLUMIANT is 2 mg once daily.

OLUMIANT may be used as monotherapy or in combination with methotrexate or other DMARDs.

OLUMIANT is given orally with or without food [see Clinical Pharmacology (12.3)].

General Considerations for Administration

  • OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL [see Warnings and Precautions (5.5)].
  • Avoid use of OLUMIANT in patients with active, serious infection, including localized infections [see Warnings and Precautions (5.1)].

Prior to initiating OLUMIANT, test patients for latent tuberculosis (TB). If positive, consider treating for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].

Dose Modifications Due to Serious Infections and Cytopenias

If a patient develops a serious infection, hold treatment with OLUMIANT until the infection is controlled.

Modify dosage in cases of lymphopenia, neutropenia or anemia (Tables 1, 2, and 3). For treatment initiation criteria [see Dosage and Administration (2.2)].

Table 1: Dose Adjustments for Lymphopenia
Low Absolute Lymphocyte Count (ALC)
Lab Value (cells/mm3) Recommendation
ALC greater than or equal to 500 Maintain dose
ALC less than 500 Interrupt OLUMIANT until ALC greater than or equal to 500
Table 2: Dose Adjustments for Neutropenia
Low Absolute Neutrophil Count (ANC)
Lab Value (cells/mm3) Recommendation
ANC greater than or equal to 1000 Maintain dose
ANC less than 1000 Interrupt OLUMIANT until ANC greater than or equal to 1000
Table 3: Dose Adjustments for Anemia
Low Hemoglobin Value
Lab Value (g/dL) Recommendation
Greater than or equal to 8 Maintain dose
Less than 8 Interrupt OLUMIANT until hemoglobin greater than or equal to 8

Dose Modifications in Patients with Renal or Hepatic Impairment

  • The recommended dose of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and 60 mL/min/1.73 m2) is 1 mg once daily. OLUMIANT is not recommended for use in patients with severe renal impairment (estimated GFR of less than 30 mL/min/1.73 m2) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
  • OLUMIANT is not recommended for use in patients with severe hepatic impairment.

Dose Modifications Due to Drug Interactions

The recommended dose of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, is 1 mg once daily [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

Hide